AGP Executive Report
Last update: 10 hours agoCancer Care in Europe: The EMA’s CHMP has issued a positive opinion for Merck’s KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) as perioperative treatment for adults with resectable muscle-invasive bladder cancer (MIBC), covering neoadjuvant therapy before radical cystectomy and continued adjuvant treatment; the European Commission review now moves to a final decision expected in Q4 2026, with Liechtenstein included. Short Bowel Syndrome Breakthrough: Zealand Pharma received a positive CHMP opinion for Zeydovio (glepaglutide) for adults with short bowel syndrome, reporting that two thirds of patients saw at least a 20% reduction in weekly parenteral support volume after 24 weeks, and one in seven weaned off entirely. Retirement Health Check: Switzerland ranks fourth in Natixis’ Global Retirement Index (79%), with health scoring improving (to 93%) but material wellbeing dropping to 15th. Work Mobility for Liechtenstein Residents: The UK published its Frontier Worker permit list; citizens of Liechtenstein (and Switzerland) qualify, with no application fee and no immigration health surcharge. Legal/Tech Watch: A UPC injunction blocks MGI Tech from selling or supplying Oxford Nanopore-linked CycloneSEQ sequencing systems across several European markets, including Liechtenstein.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
